Abstract
Purpose: The goal of this study is to develop discriminatory dissolution method to be used as a release parameter for testing and evaluating product performance by using quality by design trials intended for regulated markets. Dissolution testing is a requirement for all solid oral dosage forms and is used throughout the development life-cycle for product release and stability testing. Methods: After testing solubility in the dissolution medium, surfactant concentration, rotation speed, dissolution medium pH, and apparatus type, the appropriate conditions were established. Results: According to investigations, the optimal dissolution conditions were obtained utilising a USP apparatus II, 900 ml of 0.4 percent SLS medium in pH 4.5 acetate buffer, and a 75 rpm rotation speed. Conclusion: This research shows how a discriminate dissolution method for Rivaroxaban, a BCS Class 2 medication with pH-independent solubility, was developed in a systematic manner. The dissolution method described here can be utilised as a quality control test for Rivaroxaban tablets, with a particular focus on batch to batch evaluations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
